When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?

Published Date: 24 Feb 2026

Researchers examined whether CDK4/6 inhibitors lead to better overall survival when used as first- or second-line treatment.

Read Full News

Latest News

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Is There a Role for Stimulants in Beating Cancer Fatigue?

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

Todays Updates

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, ⁠citing unresolved issues found at a...

The New Perfectionism Problem in Medical Training

The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Todays Updates

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, ⁠citing unresolved issues found at a...

The New Perfectionism Problem in Medical Training

The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Latest News

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.

News All Time

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Recommended News For You

How the metastasis of cancer is driven by cellular plasticity.

Atezolizumab Consolidation Impresses in High-Risk DLBCL

Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

Never in a million years did I think I'd have to limit my chemotherapy.

FDA Approves CAR-T Product Use for Myeloma Early.

Recommended Articles For You

Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends 

The importance of understanding normal serum osmolality 

Future of Oncology: Targeted Therapies & Collaborative Innovation Shaping Cancer Care in the USA 

Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

2.

Study finds 81% of cancer cures touted by TikTok videos are fake

3.

The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.

4.

Inside the Major Findings From the NHS-Galleri Trial

5.

What is Mohs micrographic surgery? 8 FAQs about Mohs

1.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

2.

Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options 

3.

From Muscle Soreness to Improved Endurance: The Benefits of Monitoring Lactic Acid Levels 

4.

The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies

5.

The Role of Alanine Aminotransferase in Liver Health and Disease 

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot